Humacyte (HUMA) Stock Price, News & Analysis

Company Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $4.45 to $6.77
• 50-Day Range: $3.46 to $5.82
• 52-Week Range: $2.48 to $9.97
• Volume: 75.23 million shs
• Average Volume: 2.74 million shs
• Market Capitalization: $583.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.43
• Consensus Rating: Buy

Humacyte Stock Analysis - MarketRank™

Humacyte scored higher than 67% of companies evaluated by MarketBeat, and ranked 357th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Humacyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Humacyte has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Humacyte are expected to grow in the coming year, from ($1.27) to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Humacyte is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Humacyte is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Humacyte has a P/B Ratio of 35.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.60% of the float of Humacyte has been sold short.

Short Interest Ratio / Days to Cover

Humacyte has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Humacyte has recently increased by 6.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Humacyte does not currently pay a dividend.

Dividend Growth

Humacyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.60% of the float of Humacyte has been sold short.

Short Interest Ratio / Days to Cover

Humacyte has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Humacyte has recently increased by 6.22%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.09

News Sentiment

Humacyte has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 45 news articles for Humacyte this week, compared to 8 articles on an average week.

Search Interest

30 people have searched for HUMA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Humacyte insiders have sold 32,616.64% more of their company's stock than they have bought. Specifically, they have bought $20,194.00 in company stock and sold $6,606,799.00 in company stock.

Percentage Held by Insiders

11.20% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HUMA Stock Analysis - Frequently Asked Questions

How have HUMA shares performed this year?

Humacyte's stock was trading at $2.84 at the start of the year. Since then, HUMA shares have increased by 63.4% and is now trading at $4.64.
View the best growth stocks for 2024 here.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) issued its earnings results on Friday, March, 22nd. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01.

Who are Humacyte's major shareholders?

Humacyte's top institutional investors include State Street Corp (3.99%), Geode Capital Management LLC (1.71%), Charles Schwab Investment Management Inc. (0.60%) and Private Advisor Group LLC (0.31%). Insiders that own company stock include Brady W Dougan, Laura E Niklason, Gordon M Binder, Kathleen Sebelius, Michael T Constantino, William John Scheessele, Heather Ledbetter Prichard and Dale A Sander.
View institutional ownership trends.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Humacyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/22/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HUMA
• CUSIP: N/A
• CIK: 1818382
• Web: www.constellationalpha.com
• Phone: 919-313-9633
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.43
• High Stock Price Target: $25.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +189.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-110,780,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -942.81%
• Return on Assets: -93.82%

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 1.10
• Quick Ratio: 1.10

Sales & Book Value

• Annual Sales: $1.57 million
• Price / Sales: 371.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 35.69

Miscellaneous

• Outstanding Shares: 125,859,000
• Free Float: 111,763,000
• Market Cap: $583.99 million
• Optionable: Optionable
• Beta: 1.38